Apotex Pharmachem Inc.

Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Other

Brantford Chemicals Inc.

Perenna Pharmaceuticals, Inc.

Zhejiang Jiuzhou Pharmaceuticals Co., Ltd

Zhejiang University

Daqing Che

Bhaskar Reddy Guntoori

Yajun Zhao

Fan Wang

K S Keshava Murthy

Yuanqiang Li

Stephen E Horne

Allan W Rey

Jody Faught

Alan Chow

Aaron C Kinsman

Xianyi Zhang

Bin Zhang

Kiran Kumar Kothakonda

Uma Kotipalli

David A Stradiotto

Sammy Chris Duncan

Hongjun Gao

Ks Keshava Murthy

Laura Kaye Montemayor

Pucha Yan

Jonathan Bayldon Baell

Jiasheng Fu

Guoliang Zhu

Kang Zhen Chen

Cameron L McPhail

Xiaoyu Liu

Peter Garth Blazecka

Wenfa Ye

Lingfeng Qian

Kai Hu

Shaoqing Ge

Nadia Corelli-Rennie

Yuguang Shi

Jodi Faught

Weike Su

Xiangdong Zhang

Jianqiang Qian

Yongliang Yan

Xiaowei Hu

Yunyu Hua

Xiangjun Shi

Jinrong Lin

Inhibitors of ALCAT1 are described having the general formula: (I). These compounds offer a treatment for aging and age-related diseases. 

Compounds useful as inhibitors of ALCAT 1

The present invention relates to the technical field of organic chemistry, specifically an asymmetrical hydrogenation of an &#x2202;-ketonic acid compound, the technical proposal being as shown by the following formula:  Wherein Ris a phenyl, a substituted phenyl, a naphthyl a substituted naphthyl, a C-Calkyl or aralkyl, the substitute is a C-Calkyl, a C-Calkoxy, a halogen, the number of the substituents is 1-3. M is a chiral spiro-pyridyl amido phosphine ligand iridium complex having the following structure,  Wherein, R is hydrogen, 3-methyl, 4-Bu or 6-methyl

Asymmetrical hydrogenation reaction of ketonic acid compound

The present invention relates to the technical field of ibrutinib, particularly to the technical field of ibrutinib intermediate compounds and preparation methods thereof. The intermediate compounds are represented by formula A, wherein, the dotted line represents a double bond or a single bond between carbon and oxygen. 

Ibrutinib intermediate compounds, preparation methods and uses thereof

The present invention relates to the field of medical synthesis, in particular to a preparation method for pyrrolidine-2-carboxylic acid derivatives. The present invention adopts the following technical solution: providing a compound having a structure of formula (E), wherein R is Ror R, Ris C-Can alkyl, benzyl, p-methoxybenzyl, or p-nitrobenzyl group, and Ris hydrogen; Ris a protecting group of the carboxyl group; and Pis a protecting group on nitrogen. 

Preparation method for pyrrolidine-2-carboxylic acid derivatives

The present invention relates to the technical field of medicine and organic synthesis, particularly to a method for preparing crizotinib. The method comprises the compound of formula b and the compound of formula e undergoing Suzuki coupling reaction to produce the compound of formula a which then was subjected to deprotection to afford (&#xb1;) crizotinib. 

Crizotinib preparation method

Disclosed are a silodosin intermediate and a preparation method thereof. The silodosin intermediate has the structure shown by the formula (A). X is hydrogen or bromide and Ris hydrogen. The formyl group may be a group having the structure shown by the formula I. Ris a protecting group of carboxyl, and Ris 3-hydroxypropyl or a group having the structure shown by the formula II. W is a protecting group of hydroxyl. A compound of the formula (A) according to the present invention may further be used for preparing a compound having the structure shown by the formula (D). By means of the intermediate and the preparation method therefor provided by the present invention, high-purity optically pure silodosin can be obtained, and the optical purity is above 99%. 

Silodosin intermediate and preparation method therefor

A new compound is provided, which is used for preparing lacosamide. A novel method for preparing lacosamide is also provided. During the reaction, iodomethane and silver oxide that are cost expensive are not used, nor a Pd-c catalyst is used, so the production cost is low, the raw materials and accessory materials are cheap and easily available, and the process is simple, so that industrial production is easy to realize; and moreover, the yield is high, and good economic efficiency can be achieved. 

Lacosamide intermediate compound, preparation method thereof and use thereof

A novel process for the preparation of omeprazole and its enantiomers, such as esomeprazole, as well as the preparation of related 2-(2-pyridinylmethyl-sulphinyl)-1H-benzimidazoles, including pantoprazole, lansoprazole and rabeprazole, as recemates or single enantiomers, and their alkali or alkaline salts has been developed. The novel process involves the surprising discovery that protection of the free-base benzimidazole sulfoxide (e.g. omeprazole or esomeprazole), by reaction with an alkyl, aryl or aralkyl chloroformate following oxidation of the corresponding sulfide, eliminates the need for its direct isolation. Subsequent removal of the protecting group with a solution of alkali or alkaline earth alkoxide in a C1-C4 alcohol directly provides the corresponding salt. By eliminating the need to handle the free-base benzimidazole sulfoxide, this advantageous procedure provides increased chemical yields over processes described in the art.

Process for the preparation of esomeprazole and salts thereof

Atorvastatin calcium propylene glycol solvates and processes to prepare these novel solvates which are particularly useful and suitable for pharmaceutical applications.

Atorvastatin calcium propylene glycol solvates

Provided are a cocrystal of Adefovir dipivoxil and nicotinamide as well as a cocrystal of Adefovir dipivoxil and salicylamide cocrystal and processes for the preparation thereof.

Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof

There is provided a process for the preparation of olanzapine comprising:

Processes for the synthesis of olanzapine

A process is provided for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 comprising:    

Process for the preparation of atorvastatin and intermediates

A stable amorphous form of rifaximin is disclosed. This form is chemically and polymorphically stable on storage and can be prepared by dissolving rifaximin in a solvent to form a solution, which is precipitated by adding an anti-solvent and isolating of the precipitated amorphous rifaximin as an end product.

Amorphous form of rifaximin and processes for its preparation

Growing community of inventors

Brantford, Canada

Daqing Che